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ABSTRACT In critically ill patients, drug exposure may be inﬂuenced by altered drug
distribution and clearance. Earlier studies showed that the variability in caspofungin
exposure was high in intensive care unit (ICU) patients. The primary objective of this
study was to determine if the standard dose of caspofungin resulted in adequate
exposure in critically ill patients. A multicenter prospective study in ICU patients
with (suspected) invasive candidiasis was conducted in the Netherlands from No-
vember 2013 to October 2015. Patients received standard caspofungin treatment,
and the exposure was determined on day 3 of treatment. An area under the
concentration-time curve from 0 to 24 h (AUC0–24) of 98 mg · h/liter was considered
adequate exposure. In case of low exposure (i.e., 79 mg · h/liter, a 20% lower
AUC0–24), the caspofungin dose was increased and the exposure reevaluated.
Twenty patients were included in the study, of whom 5 had a positive blood cul-
ture. The median caspofungin AUC0–24 at day 3 was 78 mg · h/liter (interquartile
range [IQR], 69 to 97 mg · h/liter). A low AUC0–24 (79 mg · h/liter) was seen in 10
patients. The AUC0–24 was signiﬁcantly and positively correlated with the caspofun-
gin dose in mg/kg/day (P  0.011). The median AUC0–24 with a caspofungin dose of
1 mg/kg was estimated using a pharmacokinetic model and was 114.9 mg · h/liter
(IQR, 103.2 to 143.5 mg · h/liter). In conclusion, the caspofungin exposure in ICU pa-
tients in this study was low compared with that in healthy volunteers and other
(non)critically ill patients, most likely due to a larger volume of distribution. A
weight-based dose regimen is probably more suitable for patients with substantially
altered drug distribution. (This study has been registered at ClinicalTrials.gov under
registration no. NCT01994096.)
KEYWORDS antifungal therapy, intensive care, pharmacokinetics, therapeutic drug
monitoring
Invasive candidiasis is an important cause of morbidity and mortality in immunocom-promised and critically ill patients. Patients in intensive care units (ICUs) are especially
at risk for invasive candidiasis due to the presence of risk factors such as the use of a
central venous catheter, parenteral nutrition, renal replacement therapy, mechanical
ventilation, previous broad-spectrum antibiotic therapy, immunosuppression, neutro-
penia, or recent major surgery (1, 2). Candidemia is the fourth most common cause of
health care-associated bloodstream infections in ICU patients, and Candida species are
the most commonly isolated health care-associated bloodstream pathogens (3). A
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mortality of 40% has been reported in patients with invasive candidiasis. Moreover,
invasive candidiasis is associated with a prolonged hospital stay and increased costs
(4–9).
Prompt initiation of effective antifungal therapy in the appropriate dosage is
required to improve the outcome in patients with invasive candidiasis (10, 11). The
Infectious Diseases Society of America (IDSA) and the European Society for Clinical
Microbiology and Infectious Diseases (ESCMID) guidelines for the management of
candidiasis recommend the use of an echinocandin, such as caspofungin, as primary
therapy for (suspected) invasive candidiasis in critically ill patients (12, 13). In healthy
volunteers receiving the standard dose of caspofungin, the mean area under the
concentration-time curve from 0 to 24 h (AUC0–24) was 98 mg · h/liter (14–16).
In critically ill patients, drug exposure may be inﬂuenced by altered drug distribution
and clearance (17–21), and this may require drug concentration-guided dosing (22). For
ICU patients the inter- and intraindividual variabilities in caspofungin trough concen-
trations appeared to be high (23). Factors that were associated with low caspofungin
plasma concentrations were body weight above 75 kg and hypoalbuminemia, which
is present in up to 60% of ICU patients (23, 24). Capillary permeability, third spacing,
and multiorgan failure may also inﬂuence the caspofungin concentration in ICU
patients (23). Furthermore, caspofungin exposure might be inﬂuenced by disease
severity (10, 11).
The primary objective of this study was to determine if the standard dose of
caspofungin resulted in adequate exposure in critically ill patients. In addition, the
exposure was reevaluated after a dose escalation in patients with low drug exposure.
Finally, we used a population pharmacokinetic model to estimate at which dose the
target exposure was reached.
RESULTS
Twenty patients were included in the study, and their medical records were re-
viewed. The median age of the patients was 56 years (range, 25 to 83 years), and 16
patients (80.0%) were Caucasian. The patients’ characteristics are shown in Table 1.
Patients had suspected invasive candidiasis based on culture results (Table 1) and
clinical symptoms. Five patients had a positive blood culture. The median Candida score
was 3.5 out of 5 (interquartile range [IQR], 2.0 to 4.0). Patients received caspofungin for
a median period of 7 days (range, 3 to 25 days). Treatment with caspofungin was
continued in 8 patients (40.0%), and antifungal treatment was switched to ﬂuconazole
in 6 patients (30.0%) with a Candida albicans strain that was susceptible to ﬂuconazole.
Treatment was switched to liposomal amphotericin B in 2 patients (10.0%) (in 1 patient
because of lack of efﬁcacy and in 1 patient because of possible retinal involvement). In
total, 4 patients (20.0%) died during treatment with caspofungin, of whom 1 patient
had a positive blood culture for Candida glabrata (MIC, 0.125 mg/liter). Liver enzymes
increased in 3 patients (15.0%) during treatment with caspofungin; all 3 patients
received the standard dose of caspofungin. According to the Naranjo adverse drug
reaction probability scale (25), there was a possible relationship with the use of
caspofungin (score of 2 out of 13 for all 3 patients).
Caspofungin pharmacokinetics and exposure. The population pharmacokinetic
parameters of caspofungin are described using a two-compartment model, and the
results are shown in Table 2. The median AUC0–24 of caspofungin was 78.1 mg · h/liter
(range, 61.4 to 129.4 mg · h/liter). The mean plasma concentration-time curve is shown
in Fig. 1. The AUC0–24 was below 79 mg · h/liter (i.e., 20% reduction) in 10 patients
(50.0%). The caspofungin exposure and dose adjustments for the individual patients are
shown in Table 3. The AUC0–24 of caspofungin showed no signiﬁcant correlation with
the caspofungin dose (not corrected for the weight of the patient) (correlation coefﬁ-
cient, 0.164; P  0.490). The AUC0–24 of caspofungin showed a signiﬁcant correlation
with the caspofungin dose, corrected for the weight of the patient (mg/kg/day)
(correlation coefﬁcient, 0.557; P  0.011). In addition, the weight of the patients was
signiﬁcantly correlated with the volume of distribution in the central compartment (V1)
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(correlation coefﬁcient, 0.602; P  0.005) and clearance (CL) (correlation coefﬁcient,
0.604; P 0.005) of caspofungin. No signiﬁcant correlation of the caspofungin AUC0–24
with patient age, liver enzymes, albumin concentration, or disease severity scores was
found (Table 4). Furthermore, the caspofungin AUC0–24 was not signiﬁcantly different
in patients with different gender, race, presence of continuous venovenous hemoﬁl-
tration (CVVH), presence of sepsis, or interacting comedication (Table 5). Caspofungin
trough concentrations were determined in 9 patients when patients were on an
adequate dose regimen. The median trough concentration was 2.6 mg/liter (range, 1.0
to 3.4 mg/liter). The individual trough concentrations for each patient are shown in
Table 3.
Bayesian adaptive dose selection to reach the target exposure of 98 mg · h/liter
resulted in a median weight-based dose regimen of caspofungin of 0.9 mg/kg (IQR, 0.7
to 1.0 mg/kg). Selecting a caspofungin dose of 1 mg/kg resulted in a median AUC0–24
of 114.9 mg · h/liter (IQR, 103.2 to 143.5 mg · h/liter). When a ﬁxed-dose regimen of 50
mg for patients with a weight of 70 kg, 70 mg for patients weighing between 70 and
TABLE 1 Patient characteristics
Characteristica Value for patients (n  20)
No. (%) male 11 (55)
Median (range) age, yr 56 (25–83)
Median (range) wt, kg 78 (48–139)











Renal insufﬁciency 2 (10)
Respiratory insufﬁciency 6 (30)
Postoperative 2 (10)
Median (range) stay in ICU, days 16 (4–45)
No. (%) with CVVH 8 (40)
Median (range) score
APACHE II 19 (8–34)
APACHE IV 95 (47–169)
SAPS3 59 (31–104)
SOFA 8 (2–20)
No. (%) with Candida species:
C. albicans 10 (50)
C. glabrata 7 (35)
C. tropicalis 1 (5)
Not speciﬁed 2 (10)
No. (%) with culture matrix:
Blood 5 (25)
Drain ﬂuidc 6 (30)
CVC tip 2 (10)
Pus in a closed spaced 4 (20)
Throat 3 (15)
aAbbreviations: APACHE, acute physiology and chronic health evaluation; CVC, central venous catheter;
CVVH, continuous venovenous hemoﬁltration; ICU, intensive care unit; SAPS3, simpliﬁed acute physiology
score; SOFA, sepsis-related organ failure assessment.
bOne patient each with HIV, lymphoma, Mizuho disease, spondylodiscitis, and pressure ulcers.
cThree patients with abdominal ﬂuid and three patients with pleural ﬂuid.
dTwo abdominal, 1 hip, and 1 cardiovascular.
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100 kg, and 100 mg for patients with a weight of 100 kg was selected, the median
AUC0–24 was 104.3 mg · h/liter (IQR, 88.6 to 123.6 mg · h/liter).
DISCUSSION
The median AUC0–24 of caspofungin was 78 mg · h/liter and the caspofungin
exposure was low in 50% of the patients receiving the standard dose of caspofungin.
The caspofungin AUC0–24 was signiﬁcantly correlated with the caspofungin dose in
mg/kg/day, and the weight of the patients was signiﬁcantly correlated with the central
V1 and CL of caspofungin. Based on the results of our study, the current dose regimen,
of 50 mg for patients weighing 80 kg and 70 mg for patients weighing 80 kg, may
not be the most suitable dose regimen for ICU patients to reach the target exposure of
caspofungin. Based on the population pharmacokinetic model we developed, a weight-
based dose regimen of 1 mg/kg once daily would probably be a more appropriate dose
regimen for ICU patients. Simulation of this dose in the model resulted in an AUC0–24
between 98 mg · h/liter, the limit set for efﬁcacy (14–16), and 210 mg · h/liter, the limit
set by the manufacturer of caspofungin for which a dose reduction is recommended
(15), in all patients. The association with body weight was in agreement with an earlier
study of caspofungin trough concentrations in ICU patients (23) and with a study in
overweight and obese people where lower caspofungin AUCs were observed in obese
persons than in thinner persons (26). Caspofungin has shown good tolerability at
higher doses. The use of caspofungin in a dose of 70 to 200 mg per day was well
tolerated, and the incidence of drug-related adverse events was similar for the standard
and high-dose regimens (27–31). One clinical trial studied the efﬁcacy of a higher
caspofungin dose (150 mg daily). This study showed no clear beneﬁts of this dosing
TABLE 2 Population pharmacokinetic parameters of caspofungin (n  20)
Parametera Median (range)
AUC0–24 (mg · h/liter) 78.1 (61.4–129.4)
Cmin (mg/liter) 1.7 (1.1–3.9)
Cmax (mg/liter) 7.4 (4.7–14.7)
CL (liters/h) 0.66 (0.37–1.26)
V1 (liters) 9.1 (5.5–13.2)
V2 (liters) 8.6 (5.2–59.0)
t1/2 (h) 2.5 (2.2–4.0)
t1/2 (h) 19.8 (12.3–66.0)
aAbbreviations: AUC0–24, area under the concentration-time curve from 0 to 24 h; Cmax, maximal
concentration; Cmin, minimal concentration; CL, clearance; V1, volume of distribution in the central
compartment; V2, volume of distribution in the peripheral compartment; t1/2, half-life at  phase; t1/2,
half-life at  phase.
FIG 1 Caspofungin concentration-time curve on day 3 of treatment, showing mean with standard
deviation for each time point.
van der Elst et al. Antimicrobial Agents and Chemotherapy
February 2017 Volume 61 Issue 2 e01582-16 aac.asm.org 4
 o
n








strategy; however, the study was not performed particularly in ICU patients, and the
caspofungin exposure was not measured (28). Since our model was built with data from
only 20 patients and most patients had suspected invasive candidiasis, a weight-based
dose regimen of 1 mg/kg needs to be conﬁrmed in a larger data set with regard to the
efﬁcacy of the treatment.
The median AUC0–24 of caspofungin found in this study was 78 mg · h/liter. The
AUC0–24 was low compared to the AUC0–24 of 98 mg · h/liter established in healthy
volunteers (14–16), an AUC0–24 of 110 to 117 mg · h/liter found in non-critically ill
patients (32, 33), and an AUC0–24 of 89 to 116 mg · h/liter established in ICU patients
(34, 35). The volume of distribution in the peripheral compartment (V2) was larger than
TABLE 3 Caspofungin exposure and dose adjustments for individual patients
Patient Wt (kg)




(mg · h/liter)a Dose (mg)
AUC0–24
(mg · h/liter)
1 60 35c 67.0 50 113.6
2 100 70 101.9 2.6
3 95 70 81.8
4 48 50 109.3 3.4
5 79 50 71.6 —d
6 80 50 62.6 —
7 70 35c 74.2 50 109.3 2.2 (1.0–2.8)
8 94 70 68.0 100 127.8 3.0
9 74 50 82.1 2.2
10 76 50 64.3 —
11 74 50 73.2 70 91.6 2.0 (1.5–2.7)
12 99 70 128.1 3.4 (3.4–3.4)
13 83 70 82.1 2.8 (2.1–2.8)
14 80 50 98.9
15 85 70 80.8
16 52 50 91.0
17 75 50 73.1 —
18 139 70 61.4 100 74.8
19 75 50 129.4 2.2 (1.6–3.1)
20 76 50 75.4 —
aAUC0–24, area under the concentration-time curve over 24 h.
bCaspofungin trough concentration expressed as median with range.
cReduced caspofungin dose due to severe liver failure/cirrhosis (Child-Pugh score C).
d—, caspofungin was discontinued.




Age (years) 0.093 0.698
Caspofungin dose (mg/kg/day) 0.057 0.011
Liver enzymes
ALT (U/liter) 0.267 0.255
AST (U/liter) 0.259 0.270
Bilirubin (mol/liter) 0.109 0.657
Alkaline phosphatase (U/liter) 0.085 0.729
-Glutamyl transpeptidase (U/liter) 0.060 0.801
Albumin (g/liter) 0.213 0.367
Disease severity scores
APACHE II 0.220 0.352
APACHE IV 0.194 0.426
SAPS3 0.341 0.141
SOFA 0.216 0.361
aAbbreviations: AUC0–24, area under the concentration-time curve from 0 to 24 h; ALT, alanine
aminotransaminase; APACHE, acute physiology and chronic health evaluation; AST, aspartate
aminotransaminase; SAPS, simpliﬁed acute physiology score; SOFA, sepsis-related organ failure assessment.
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that in healthy volunteers and patients in other studies (15, 16, 32–35). The half-life (t1/2)
was comparable to the t1/2 in other ICU patients (34) and was longer than the t1/2 in
healthy volunteers (15, 16). The low AUC0–24 of caspofungin in our study is therefore
most likely the result of a larger V. Fluid extravasation as a result of endothelial
dysfunction and capillary leak, edema in sepsis, ascites, and other third spaces, ﬂuid
resuscitation, and hypoalbuminemia are factors that are frequently present in ICU
patients and can all lead to an increased V and a lower drug concentration (18–20). Low
AUC values and increased V in ICU patients are also seen with other antifungal drugs,
such as ﬂuconazole and anidulafungin (36, 37). Although one study showed a lower
response rate among patients with a higher acute physiology and chronic health
evaluation II (APACHE II) score (38), the AUC0–24 of caspofungin was not associated with
disease severity scores, which was in agreement with recent ﬁndings (34, 36). Hence,
the use of disease severity scores does not seem appropriate to predict pharmacoki-
netic parameters.
Two patients in our study suffered from severe liver damage or cirrhosis (Child-Pugh
score C), and they therefore received a daily caspofungin dose of 35 mg according to
the summary of product characteristics of caspofungin. The AUC0–24 was low in both
patients, and the dose was increased to 50 mg, after which the AUC0–24 was adequate
and liver enzymes remained stable. These results are in accordance with two case
reports where 50 mg and 70 mg were given to patients with moderate hepatic
dysfunction and where the exposure was similar to the exposure in healthy volunteers
(39, 40). These ﬁndings illustrate that liver drug metabolism may be underestimated in
the presence of liver test abnormalities or evidence of cirrhosis (41). Furthermore, a
recent study in ICU patients with Child-Pugh score B showed that the recommended
caspofungin dose of 35 mg resulted in low caspofungin exposure, and a simulation of
several dosing regimens showed that adequate expose was reached with a daily
caspofungin dose of 50 to 70 mg (42). Since the Child-Pugh score is highly driven by
the albumin level, ICU patients with hypoalbuminemia are often incorrectly classiﬁed
with a Child-Pugh B score. Based on the results of that study, the authors state that the
caspofungin maintenance dose should not be reduced in noncirrhotic ICU patients
based on the Child-Pugh score if the classiﬁcation is driven by hypoalbuminemia, as the
decreased maintenance dose results in a signiﬁcantly lower caspofungin exposure (42).
Combined with the case reports and recent study (39, 40, 42), our ﬁndings suggest that
patients with moderate hepatic dysfunction should perhaps initially receive a higher
empirical maintenance dose, with close follow-up with therapeutic drug monitoring
(TDM) and monitoring of liver enzymes. Further research in this patient group is needed
to provide evidence for the development of new dosing recommendations.
Since caspofungin was used as empirical treatment for suspected invasive candidi-
asis, the MIC of the Candida species was determined in only 4 patients. In vivo studies
have demonstrated that the AUC/MIC ratio is a good descriptor of the echinocandin
exposure-response relationship. In these in vivo studies, an AUC0–24/MIC ratio of 865
TABLE 5 Caspofungin AUC0–24 in different patient groupsa
Characteristic







Gender (male) 74.2 (64.3–82.1) 91.0 (72.4–105.6) 0.175
Race (Caucasian) 78.6 (72.0–96.9) 74.4 (67.3–96.6) 0.682
CVVH 74.8 (67.3–102.2) 82.0 (72.0–96.9) 0.734
Sepsis 77.5 (70.5–103.8) 78.6 (67.8–84.3) 0.796
Corticosteroid use 81.8 (68.0–101.9) 77.0 (72.0–94.7) 0.600
aAbbreviations: AUC0–24, area under the concentration-time curve from 0 to 24 h; CVVH, continuous
venovenous hemoﬁltration.
bCaspofungin AUC0–24h expressed as median with interquartile range.
cDetermined by using the Mann-Whitney U test.
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was established for a 1-log kill of C. albicans for caspofungin, an AUC0–24/MIC ratio of
450 for a 1-log kill of C. glabrata, and an AUC0–24/MIC ratio of 1,185 for a 1-log kill of
C. parapsilosis (MIC values determined according to CLSI criteria) (14). Considering an
AUC0–24 of approximately 100 mg · h/liter, the AUC0–24/MIC ratio target can be reached
when C. albicans strains have MIC values of 0.125, when C. glabrata strains have MIC
values of 0.25, and when C. parapsilosis strains have MIC values of 0.10. However,
C. parapsilosis strains often have MIC values of 0.10, and therefore the AUC0–24 of
approximately 100 mg · h/liter is not sufﬁcient to reach the AUC0–24 target ratio (43).
The median AUC0–24 of the patients in this study was lower; however, in case of an
infection with a Candida species with a low MIC value, the AUC0–24/MIC ratio can still
be sufﬁcient with a lower AUC0–24 value. Meanwhile, a large variability in caspofungin
MIC values among testing laboratories is seen, and routine in vitro susceptibility testing
of caspofungin against Candida by using the CLSI or EUCAST method is currently not
recommended until this reproducibility problem in susceptibility testing is resolved
(44). Besides, in case of empirical treatment, the MIC of the Candida species is not
known at the start of the treatment. Then, the strategy would be to acquire at least
adequate exposure to cover susceptible Candida species, since a delay in appropriate
antifungal therapy affects mortality (10).
In conclusion, the AUC0–24 of caspofungin in ICU patients in this study was low
compared with that in healthy volunteers and other (non)critically ill patients, most
likely due to a larger volume of distribution. A weight-based dose regimen of 1
mg/kg/day for patients with an increased volume of distribution and clearance, and
TDM in patients with liver failure, is probably a more suitable approach to achieve
optimal exposure of caspofungin, although this approach needs to be conﬁrmed with
a larger data set.
MATERIALS AND METHODS
Study design. This multicenter prospective study was conducted at the 46-bed ICU department of
the University Medical Center Groningen and the 18-bed ICU department of the Medisch Spectrum
Twente, the Netherlands, from November 2013 to October 2015. Patients were eligible for inclusion if the
following criteria were met: (1) age 18 years, (2) admission to the ICU department, (3) (suspected)
invasive candidiasis according to the 2008 deﬁnition of Invasive Fungal Disease from the European
Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and
the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus
Group (45), and (4) treatment with caspofungin. In both centers caspofungin was the standard treatment
for (suspected) invasive candidiasis. Patients were excluded if they did not have an arterial line for blood
sampling. The local ethics committee of both hospitals approved the study (Institutional Review Board
2012-371), and the study was registered at ClinicalTrials.gov under registration no. NCT01994096. Written
informed consent was obtained from the patient or the legal representative of the patient.
Caspofungin was administered once daily by intravenous infusion over 1 h. The recommended dose
regimen of caspofungin consists of a loading dose of 70 mg on day one, followed by a daily maintenance
dose of 50 mg for patients weighing80 kg or a daily maintenance dose of 70 mg for patients weighing
80 kg. In patients with moderate hepatic insufﬁciency (Child-Pugh score B), a dose reduction to 35 mg
per day is recommended by the manufacturer of caspofungin. The manufacturer has no clinical
experience with adult patients with severe hepatic insufﬁciency (Child-Pugh score C) (46). In this study,
patients with severe hepatic insufﬁciency received a daily dose of 35 mg. As a steady state of caspofungin
is reached on the ﬁrst day after the loading dose (16), blood samples were taken on day 3 (1 day) just
before administration of caspofungin and 1, 2, 3, 4, 6, 8, 12, and 24 h after the start of the infusion.
Caspofungin plasma concentrations were determined within 24 h, using a validated liquid
chromatography-tandem mass spectrometry assay (47). An AUC0–24 of 98 mg · h/liter or higher was
considered adequate exposure. C. albicans is the most common species seen in candidemia, and in vivo
studies showed an AUC0–24/MIC ratio of 865 for a 1-log kill of C. albicans for caspofungin. The
epidemiological cutoff value for C. albicans is 0.125 mg/liter. Therefore, an AUC of approximately 100
mg · h/liter is sufﬁcient for the treatment of susceptible C. albicans species. Furthermore, this AUC value
is in line with the AUC of 98 mg · h/liter that was seen in healthy volunteers receiving the standard dose
of caspofungin (14–16). A reduction of at least 20% relative to the target AUC0–24 (i.e., AUC0–24 of 79
mg · h/liter) was considered a clinically relevant reduction (46, 48). In patients with an AUC0–24 of 79
mg · h/liter, the caspofungin dose was increased. In case of a 20 to 40% lower AUC0–24, the dose was
increased by 40%, and in case of a 40% lower AUC0–24, the caspofungin dose was doubled. If the
caspofungin dose was adjusted, the AUC0–24 was reevaluated 3 days ( 1day) after dose adjustment.
When target exposure was attained, trough levels were measured every 3 days during treatment on the
ICU, with a maximum of 28 days. This enabled the evaluation of potential ﬂuctuations in caspofungin
concentration over time. In case of an infection with a ﬂuconazole-susceptible Candida strain, antifungal
treatment could be switched to ﬂuconazole (step-down therapy), as judged by the attending physician.
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In case an echinocandin was indicated, treatment with caspofungin was continued. Mortality was
assessed at day 28 after the start of the caspofungin treatment.
Data collection. Patient data were collected through review of the medical records using a
standardized case report form. Demographic and clinical data were collected, including age, race,
gender, weight, underlying condition, reason for ICU admission, whether or not receiving continuous
venovenous hemoﬁltration (CVVH), Candida species and localization, and the Candida score (49). Vital
signs (temperature, blood pressure, heart rate, respiratory rate, and oxygenation) and laboratory param-
eters (leukocyte count, C-reactive protein, albumin, bilirubin, alkaline phosphatase, aspartate amino-
transaminase, alanine aminotransaminase, -glutamyl transpeptidase, serum electrolytes, serum urea,
and serum creatinine concentration) were routinely measured on the ICU. These parameters were used
to calculate disease severity scores on the day that the ﬁrst AUC0–24 of caspofungin was obtained,
including the acute physiology and chronic health evaluation II (APACHE II) (50) and APACHE IV (51)
scores, the simpliﬁed acute physiology score (SAPS3) (52), and the sepsis-related organ failure assess-
ment (SOFA) (53). Furthermore, data on caspofungin dose adjustments, duration of treatment with
caspofungin, and relevant comedication were recorded. The potential causal relationship of adverse
events with the use of caspofungin was analyzed by the attending physician and the local investigator
using the Naranjo adverse drug reaction probability scale (25).
Pharmacokinetic and statistical analyses. The caspofungin AUC0–24 was calculated using the
log-linear trapezoidal rule with KINFIT, MWPharm 3.80 (Mediware, the Netherlands) (54). A two-
compartment model based on the observed caspofungin concentrations was created in MWPharm using
the KINPOP module with an iterative 2-stage Bayesian procedure. As a starting point for the model,
pharmacokinetic parameters, including the clearance (CL), volume of distribution in the central com-
partment (V1), volume of distribution in the peripheral compartment (V2), and half-lives (t1/2) for
distribution and elimination, were derived from those in the literature (46). Based on the initial model and
the patient data, a population pharmacokinetic model for our population was parameterized. Subse-
quently, individual pharmacokinetic parameters were determined for each included patient from ﬁtting
the model to the patient data. Interindividual variability of the pharmacokinetic parameters was assumed
to be log-normally distributed, and an assay error of 0.1 mg/liter (lower limit of quantiﬁcation) plus 0.15
times the measured concentration (mg/liter) was taken into account. Individual pharmacokinetic param-
eters were used to describe the medians and ranges for the pharmacokinetic parameters in this
population. Continuous covariates included age, weight, length, and creatinine clearance of the patient
and the caspofungin dose. Categorical covariates included the gender of the patient. Finally, we used the
individual pharmacokinetic data in combination with the population pharmacokinetic model to derive at
which dose the target exposure of 98 mg · h/liter was reached.
We assessed the correlation of the caspofungin AUC0–24 with the caspofungin dose, corrected for the
weight of the patient (mg/kg/day, total body weight of the patient at hospital admission), with factors
that can inﬂuence the pharmacokinetics of caspofungin, such as the patient’s age, liver enzymes, albumin
concentration, and disease severity score. Furthermore, we compared the caspofungin AUC0–24 between
patient groups with different gender, different race, whether or not receiving CVVH, the presence of
sepsis, and interacting comedication. A Spearman correlation coefﬁcient was calculated to determine
correlations between two continuous variables. For comparing two groups, the Mann-Whitney U test was
used. All statistical analyses were performed using SPSS Statistics for Windows, version 22.0 (IBM SPSS,
Armonk, NY). A P value of 0.05 was considered statistically signiﬁcant.
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